TD Cowen Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $20
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Teva Settles Patent Litigation With Amicus
How Much Upside Is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
BofA Securities Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Raises Target Price to $15
Amicus Therapeutics, ShiftPixt, Blackstone: Retail Investors Turn Most Bullish On These 3 Stocks
Sector Update: Health Care Stocks Decline Thursday Afternoon
B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $15
Express News | Amicus Therapeutics Inc - Litigation Continues Against Aurobindo, Stay Remains for Lupin
Express News | Amicus Therapeutics Inc - Teva to Market Generic Galafold in U.S. Starting Jan 30, 2037
Express News | Amicus Therapeutics Announces Settlement of Galafold® (Migalastat) Patent Litigation With Teva
Amicus Therapeutics Announces Settlement of Galafold (Migalastat) Patent Litigation With Teva
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Is Expected To Breakeven In The Near Future
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
Amicus Therapeutics Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Cuts Target Price to $18
Amicus Therapeutics Inc (FOLD) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
JPMorgan Chase & Co's Strategic Reduction in Amicus Therapeutics Inc